Clinical Practice Guidelines and the Under Treatment of Concomitant AF Vinay Badhwar, MD

Similar documents
What s New in the Guidelines for Surgical Ablation for Atrial Fibrillation?

Surgical AF Ablation : Lesion Sets and Energy Sources. What are the data? Steven F Bolling, MD Cardiac Surgery University of Michigan

New Guidelines: Surgical Ablation of Atrial Fibrillation. Niv Ad, MD

AATS STARS Meeting Miami Beach November 17, 2017

SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK

Biatrial Maze or PVI to Ablate Afib? Marc Gillinov, MD

New Guidelines: Surgical Ablation of Atrial Fibrillation. Niv Ad, MD West Virginia University Washington Adventist Hospital

Concurrent AF Ablation with Mitral Valve Surgery

Surgical Ablation for Lone AF: What have we learned after 30 years?

Surgical Ablation of Atrial Fibrillation. Gregory D. Rushing, MD. Assistant Professor, Division of Cardiac Surgery

Minimally Invasive Stand Alone Cox-Maze Procedure For Patients With Non-Paroxysmal Atrial Fibrillation

Surgical Ablation: Which Lesion Set for Which Patient?

Should Paroxysmal Atrial Fibrillation be Treated During Cardiac Surgery?

Preoperative Anemia versus Blood Transfusion: Which is the Culprit for Worse Outcomes in Cardiac Surgery?

Manuel Castella MD PhD Hospital Clínic, University of

Concomitant procedures using minimally access

The Journal of Thoracic and Cardiovascular Surgery

Stand alone maze: when and how?

Mitral Repair/AF Ablation Sternotomy Approach

Minimally Invasive Mitral Valve Repair: Indications and Approach

Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?

Postoperative Management of Patients Following Surgical Ablation

Supplementary Online Content

2018 CODING AND REIMBURSEMENT FOR. Cardiac Surgical Ablation and Left Atrial Appendage Management

Atrial Fibrillation Correction Surgery: Lessons From The Society of Thoracic Surgeons National Cardiac Database

Atrial Fibrillation Ablation: in Whom and How

What is the Role of Surgical Repair in 2012

Atrial Fibrillation Ablation Thinktank

Outcomes of Surgical Aortic Valve Replacement in Moderate Risk Patients: Implications for Determination of Equipoise in the Transcatheter Era

Definition of Success and Surgical Results That Shouldn t Be a Hard Talk, Right?

The CHADS Score Role in Managing Anticoagulation After Surgical Ablation for Atrial Fibrillation

Valvular Intervention

Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de

Chronic Primary Mitral Regurgitation

Catheter-based mitral valve repair MitraClip System

Reshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid

ACCP Cardiology PRN Journal Club

Late secondary TR after left sided heart disease correction: is it predictibale and preventable

Interventional solutions for atrial fibrillation in patients with heart failure

Repair or Replacement

The EP Perspective: Should We Do Hybrid Ablation, and Who Should We Do It On?

Does preoperative atrial fibrillation increase the risk for mortality and morbidity after coronary artery bypass grafting?

What is Minimally Invasive Surgical Ablation?

La terapia non anticoagulante nel paziente con FA secondo le Linee Guida F. CONROTTO

Atrial fibrillation (AF) is associated with increased morbidity

Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM

2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease

Atrial Fibrillation Procedures Data Summary. Participant STS Period Ending 12/31/2016

Combined catheter ablation and left atrial appendage closure as a. treatment of atrial fibrillation

Outcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the U.S.

Treatment of Atrial Fibrillation in Heart Failure

Is it Time for a National Network of Valve Centers? MICHAEL MACK, MD BAYLOR SCOTT & WHITE HEALTH

2017 HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation

FDA Executive Summary. Prepared for the October 26, 2011 meeting of the Circulatory System Devices Panel

Ischemic Mitral Valve Disease: Repair, Replace or Ignore?

부정맥 3 Debaste 2. 08:30~10:00: 4 회의장

In Process, Unpublished STS/ACC TVT Registry Manuscripts

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE

Indication, Timing, Assessment and Update on TAVI

Invasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic

Severe left ventricular dysfunction and valvular heart disease: should we operate?

Progression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro

The Emerging Atrial Fibrillation Epidemic: Treat It, Leave It or Burn It. Chandra Kumbar MD FACC FHRS The Heart Group, Evansville IN

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

AF :RHYTHM CONTROL BY DR-MOHAMMED SALAH ASSISSTANT LECTURER CARDIOLOGY DEPARTMENT

Update on Oral Anticoagulation for Mechanical Heart Valves

Options for my no option Patients Treating Heart Conditions Via a Tiny Catheter

Intraoperative Radiofrequency Ablation for the Treatment of Atrial Fibrillation During Concomitant Cardiac Surgery

Isolator Synergy Ablation System THE ONLY FDA-APPROVED SURGICAL DEVICE TO TREAT ATRIAL FIBRILLATION

The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation

Mechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute

Health Status after Transcatheter Mitral- Valve Repair in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial

Mitral Valve Disease, When to Intervene

Mitral Valve prolapse: What s new? Which indications of early surgery? Input of new 2017 ESC/EACTS guidelines. Christophe Tribouilloy Amiens, France

Recurrent Stroke under Anticoagulation in Mild MS & AF

Mitral Valve Surgery: Lessons from New York State

Atrial fibrillation and advanced age

Atrial Fibrillation: Rate vs. Rhythm. Michael Curley, MD Cardiac Electrophysiology

STS National Database

Quality Outcomes Mitral Valve Repair

On-Pump vs. Off-Pump CABG: The Controversy Continues. Miguel Sousa Uva Immediate Past President European Association for Cardiothoracic Surgery

Rapid deployment aortic valve replacement for the treatment of severe aortic stenosis in high risk patients. Β. Κόλλιας, Σ. Ματιάτου, Δ. Αγγουράς.

Results of Aortic Valve Preservation and Repair

Contemporary outcomes for surgical mitral valve repair: A benchmark for evaluating emerging mitral valve technology

Impact of Clinical Presentation and Surgeon Experience on the Decision to Perform Surgical Ablation

Predictors for permanent pacemaker implantation after concomitant surgical ablation for atrial fibrillation

Long Term Outcomes of Aortic Root Operations for Marfan Syndrome: A Comparison of Bentall versus Aortic Valve-Sparing Procedures

Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea

Should hybrid ablation be the standard of care instead of transcatheter ablation techniques?

ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION

In Process, Unpublished STS/ACC TVT Registry Manuscripts

Alec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France

Role of LAA isolation in AF cure

Durability and Outcome of Aortic Valve Replacement With Mitral Valve Repair Versus Double Valve Replacement

AF Ablation in 2015 Why, Who, What and How? Steve Wilton ACC Rockies, Banff March 10, 2015

Dual Antiplatelet Therapy Made Practical

After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?

PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL

Appropriate Patient Selection or Healthcare Rationing? Lessons from Surgical Aortic Valve Replacement in The PARTNER I Trial Wilson Y.

Introducing the COAPT Trial

Transcription:

Clinical Practice Guidelines and the Under Treatment of Concomitant AF Vinay Badhwar, MD Gordon F. Murray Professor and Chairman Department of Cardiovascular & Thoracic Surgery WVU Heart and Vascular Institute West Virginia University Morgantown, WV

Disclosures No Relevant Financial Disclosures Writing committee: 2017 AATS Expert Consensus Guidelines 2017 STS Clinical Practice Guidelines 2017 HRS Expert Consensus Statement

Objectives What are the merits of concomitant surgical ablation? What are we currently doing? What should we be doing?

Paroxysmal Persistent Early Persistent LS Persistent Permanent AF Definitions AF that terminates spontaneously or with intervention within 7 d Continuous AF sustained beyond 7d AF that is sustained beyond 7 days but is less than 3 months in duration. Continuous AF sustained > 12m Joint decision, no effort to maintain SR as a therapeutic attitude and should no longer be used Heart Rhythm. 2017;S1547

65 yo P2 flail, severe MR, 2 V CAD, LA size 4.6, early persistent AF A) MV repair, CABG only, DCCV B) MV repair, CABG, LAA clip C) MV repair, CABG, epicardial pulmonary vein isolation D) MV repair, CABG, Cox-Maze IV

The Cox-Maze Procedure

Surgical Ablation for AF at the time of Concomitant Surgery Why bother?

Why Perform Surgical Ablation?

Eur J Cardiothorac Surg 2017;52:471-477

Beyond 90-days, survival was better with SA, and improved survival persisted after risk adjustment (HR=0.58, p=0.03). A trend existed for reduced late health care costs (p=0.05). Eur J Cardiothorac Surg 2017;52:471-477

Surgical Ablation and Isolated CABG J Thorac Cardiovasc Surg 2017;153:1087-94

Mortality is Reduced when Surgical Ablation for Atrial Fibrillation is Performed Concomitantly with Mitral Operations J. Scott Rankin, Maria Grau-Sepulveda, Niv Ad, Ralph J. Damiano, A. Marc Gillinov, Patrick M. McCarthy, Vinod H. Thourani, Jeffrey P. Jacobs, David M. Shahian and Vinay Badhwar

Mortality is Reduced when Surgical Ablation for Atrial Fibrillation is Performed Concomitantly with Mitral Operations STS Adult Cardiac Surgery Database July 1, 2011 June 30, 2014 89,668 Patients isolated MVRR Included: Patients with associated CABG, ASD closure, and tricuspid valve repair (TVr). Excluded: Previous MitraClip procedures, missing gender or age information, and/or right atrial SA only 88,765 Patients

Mortality is Reduced when Surgical Ablation for Atrial Fibrillation is Performed Concomitantly with Mitral Operations Unadjusted Operative Mortality and Major Morbidity Multivariable Logistic Regression Risk Adjusted Odds Ratios (OR) for Mortality and Morbidity.

Variable Results Baseline Characteristics Control No-AF/No-SA n=53,519 AF No-SA n=10,780 AF+SA n=16,352 Age 63 71 70 Elective Presentation (%) 67 58 72 NYHA Class III/IV (%) 66 75 68 Median EF (%) 57 55 55 Cardiac Reoperation (%) 14 30 9 Persistent AF (%) - 53 58 Mitral Repair (%) 62 42 60 Mitral Replacement (%) 38 58 40 Concomitant CABG (%) 32 28 25 Tricuspid Valve Repair (%) 9 20 25 Cross Clamp Time (min) 93 94 104

Results Risk-Adjusted Outcome In-Hospital Outcomes Variable Adjusted OR [95% CI] p-value Global Wald X 2 p-value Operative Mortality AF No-SA vs. Control AF+SA vs. Control AF+SA vs. AF No-SA 1.15 [1.04-1.27] 0.0058 1.08 [0.96-1.21] 0.1868 0.94 [0.82-1.07] 0.3441 0.0175 Composite Major Morbidity AF No-SA vs. Control AF+SA vs. Control AF+SA vs. AF No-SA 1.13 [1.07-1.19] <.0001 1.08 [1.02-1.15] 0.0078 0.96 [0.90-1.03] 0.2427 <.0001

Mortality is Reduced when Surgical Ablation for Atrial Fibrillation is Performed Concomitantly with Mitral Operations J. Scott Rankin, Maria Grau-Sepulveda, Niv Ad, Ralph J. Damiano, A. Marc Gillinov, Patrick M. McCarthy, Vinod H. Thourani, Jeffrey P. Jacobs, David M. Shahian and Vinay Badhwar 1. AF at the time of MVRR independently increases Operative Mortality and Morbidity. 2. Addition of SA reduces Relative Risk of Mortality to a level equivalent to control patients without AF. 3. Early Mortality Benefit of Contemporary SA.

What are we doing?

US Rates of Surgical Ablation 50,000 Untreated Treated 37 40,000 33% Number of Patients 30,000 20,000 10,000 68 33 52% 28% 30 24% 0 (1) (1) Mitral Valve Aortic Valve Isolated CABG Total 2016 Source: STS Database (Mitral + Aortic + Isolated CABG)

Ann Thorac Surg 2017;104:493 500

Ann Thorac Surg 2017;104:493 500

Represents a 50% increase over time (p<0.0001) Ann Thorac Surg 2017;104:493 500

Comparative Outcomes of Concomitant SA All 84,105 concomitant SA operations Comprehensive propensity matching following multivariate regression. Continuous variables were evaluated using restricted cubic spline plots to assess linearity AF type (paroxysmal vs. persistent), operative type and major STS risk covariates in propensity model 1:1 Greedy 5-1 matching algorithm, SD < 1% 28,739 propensity matched pairs of concomitant SA vs. No SA for AF Ann Thorac Surg 2017;104:493 500

Relative Risk of Concomitant Surgical Ablation in Propensity Matched Patients with Atrial Fibrillation Outcome Overall (N=57,478) No Ablation (N=28,739) Ablation (N=28,739) Relative Risk (95% CI) p-value Mortality 4.31% 4.50% 4.13% 0.92 (0.85-1.00) 0.0422 Reoperation for Bleeding 3.61% 3.73% 3.49%) 0.93 (0.86-1.02) 0.1195 Permanent Stroke 1.96% 2.13% 1.78% 0.84 (0.74-0.94) 0.0028 Transient Ischemic Attack 0.38% 0.42% 0.34% 0.80 (0.61-1.05) 0.1064 Prolonged Ventilation 16.31% 16.75% 15.87% 0.95 (0.90-0.99) 0.0224 Renal Failure 4.62% 4.35% 4.88% 1.12 (1.03-1.22) 0.0107 Pacemaker 6.87% 5.89% 7.84% 1.33 (1.24-1.43) <0.0001 Phrenic Nerve Injury 0.06% 0.06% 0.06% 1.06 (0.53-2.14) 0.8655 Readmission 30-days 13.36% 12.79% 13.92% 1.09 (1.03-1.15) 0.0011 Ann Thorac Surg 2017;104:493 500

Relative Risk of Concomitant Surgical Ablation in Propensity Matched Patients with Atrial Fibrillation Outcome Overall (N=57,478) No Ablation (N=28,739) Ablation (N=28,739) Relative Risk (95% CI) p-value Mortality 4.31% 4.50% 4.13% 0.92 (0.85-1.00) 0.0422 Reoperation for Bleeding 3.61% 3.73% 3.49%) 0.93 (0.86-1.02) 0.1195 Permanent Stroke 1.96% 2.13% 1.78% 0.84 (0.74-0.94) 0.0028 Transient Ischemic Attack 0.38% 0.42% 0.34% 0.80 (0.61-1.05) 0.1064 Prolonged Ventilation 16.31% 16.75% 15.87% 0.95 (0.90-0.99) 0.0224 Renal Failure 4.62% 4.35% 4.88% 1.12 (1.03-1.22) 0.0107 Pacemaker 6.87% 5.89% 7.84% 1.33 (1.24-1.43) <0.0001 Phrenic Nerve Injury 0.06% 0.06% 0.06% 1.06 (0.53-2.14) 0.8655 Readmission 30-days 13.36% 12.79% 13.92% 1.09 (1.03-1.15) 0.0011 Ann Thorac Surg 2017;104:493 500

Relative Risk of Concomitant Surgical Ablation in Propensity Matched Patients with Atrial Fibrillation Outcome Overall (N=57,478) No Ablation (N=28,739) Ablation (N=28,739) Relative Risk (95% CI) p-value Mortality 4.31% 4.50% 4.13% 0.92 (0.85-1.00) 0.0422 Reoperation for Bleeding 3.61% 3.73% 3.49%) 0.93 (0.86-1.02) 0.1195 Permanent Stroke 1.96% 2.13% 1.78% 0.84 (0.74-0.94) 0.0028 Transient Ischemic Attack 0.38% 0.42% 0.34% 0.80 (0.61-1.05) 0.1064 Prolonged Ventilation 16.31% 16.75% 15.87% 0.95 (0.90-0.99) 0.0224 Renal Failure 4.62% 4.35% 4.88% 1.12 (1.03-1.22) 0.0107 Pacemaker 6.87% 5.89% 7.84% 1.33 (1.24-1.43) <0.0001 Phrenic Nerve Injury 0.06% 0.06% 0.06% 1.06 (0.53-2.14) 0.8655 Readmission 30-days 13.36% 12.79% 13.92% 1.09 (1.03-1.15) 0.0011 Ann Thorac Surg 2017;104:493 500

Surgical ablation utilization is increasing across all operative categories, with largest increases observed in concomitant mitral operations Surgical ablation decreases risk of mortality by 8% and stroke by 16% LAA obliteration was performed greater than 80% with all concomitant operations, but only 64% in stand-alone. This represents an opportunity for improvement. Ann Thorac Surg 2017;104:493 500

What do the Guidelines say we should be doing?

Clinical Practice Guidelines 2014 ACC AHA HRS Guideline COR IIa, LOE C Grouped all cardiac operations as a whole Utilized early surgical ablation data acquired from cases performed between 1998-2005 Classified recommendations by AF symptoms and presence of antiarrhythmic therapy Essentially a catheter based ablation guideline

Clinical Practice Guidelines 2017 STS Clinical Practice Guidelines for the Surgical Treatment of Atrial Fibrillation Distinct from 2014 HRS and 2016 ESC guidelines: Recommendations by specific operative procedures: Mitral Valve, Aortic Valve, CABG Weight and relevance of AF symptoms at the time of planned symptomatic cardiac operation Evidence based options for surgeons in typical clinical scenarios based on mortality, morbidity and 1-year outcome

2017 STS Clinical Practice Guidelines Mitral Valve Operations Multiple populations studied: 11 RCTs, 4 Metaanalyses, Several Institutional experiences Recommendation: Surgical ablation for AF can be performed without additional risk of operative mortality or major morbidity, and is recommended at the time of concomitant mitral operations to restore sinus rhythm. (COR: I, LOE: A)

2017 STS Clinical Practice Guidelines AVR, isolated CABG, AVR+CABG Operations Limited populations studied: 2 RCTs, 2 Meta-analyses, limited Institutional experiences Recommendation: Surgical ablation for AF can be performed without additional risk operative of mortality or major morbidity, and is recommended at the time of concomitant isolated AVR, isolated CABG, and AVR+CABG operations to restore sinus rhythm. (COR: I, LOE: B-NR)

2017 STS Clinical Practice Guidelines All Operations Recommendation: Surgical ablation for symptomatic AF in the setting of left atrial enlargement ( 4.5 cm) or more than moderate mitral regurgitation by pulmonary vein isolation alone is not recommended. (COR: III - No Benefit, LOE: C-EO)

2017 STS Clinical Practice Guidelines All Operations Recommendation: It is reasonable to perform LA appendage excision or exclusion in conjunction with surgical ablation for AF for longitudinal thromboembolic morbidity prevention. (COR: IIA, LOE: C-LD)

Clinical Practice Guidelines 2017 AATS Expert Consensus Guidelines Examining Surgical Treatment for Atrial Fibrillation Aligned with STS Clinical Practice Guidelines with complimentary non-duplicative recommendations Important additional clarity provided on mortality, stroke prevention, quality of life, surgical experience, energy source Meta-analyses, Forest plot comparisons

2017 AATS Expert Consensus Guidelines (COR: I, LOE: A)

2017 AATS Expert Consensus Guidelines Survival at 1 year and > 1 year Recommendation: It is reasonable to choose to perform a concomitant surgical ablation procedure for patients with a history of AF over no treatment of AF because long-term survival is unaffected or improved by surgical ablation. (COR: IIA, LOE: A 1 year, B-NR > 1 year)

2017 AATS Expert Consensus Guidelines Stroke Recommendation: It is reasonable to choose to perform a concomitant surgical ablation procedure for patients with a history of AF over no treatment of AF because there is no increased risk of perioperative stroke/tia. (COR: IIA, LOE: A)

Clinical Practice Guidelines 2017 HRS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation Aligned with STS and AATS Clinical Practice Guidelines with complimentary recommendations Distinct from STS and AATS in that HRS retains recommendations based establishment of AF symptoms and medicinal treatment However, language of acknowledgement on relevance of symptoms in concomitant operation

2017 HRS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation Heart Rhythm. 2017;S1547

2017 HRS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation Heart Rhythm. 2017;S1547

2017 HRS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation Heart Rhythm. 2017;S1547

Clinical Practice Guidelines Summary Substantial progress on multidisciplinary collaboration and societal recommendations Classification of surgical ablation by operative category: open atrial, close atrial, stand-alone Important new knowledge on the impact of surgical ablation on mortality, survival and late morbidity Guidelines provide recommendations based on an interpretation of the evidence but do not replace the decision between patient and physician